UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

Annals of oncology, 2020-11, Vol.31 (11), p.1536-1544

2020

Volltextzugriff (PDF)

Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study

Annals of oncology, 2018-10, Vol.29, p.viii741-viii741

2018

Volltextzugriff (PDF)

Phase-out-compliant fluorosurfactants: unique methimazolium derivatives including room temperature ionic liquids

Green chemistry : an international journal and green chemistry resource : GC, 2017, Vol.19 (14), p.3225-3237

2017

Volltextzugriff (PDF)

Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors

Annals of oncology, 2005-05, Vol.16 (suppl-4), p.iv61-iv68

2005

Volltextzugriff (PDF)

Ionic Liquids as Advantageous Solvents for Headspace Gas Chromatography of Compounds with Low Vapor Pressure

Analytical chemistry (Washington), 2005-01, Vol.77 (2), p.702-705

2005

Volltextzugriff (PDF)

A metabolic screening study of trichostatin A (TSA) and TSA-like histone deacetylase inhibitors in rat and human primary hepatocyte cultures

The Journal of pharmacology and experimental therapeutics, 2007-04, Vol.321 (1), p.400-408

2007

Volltextzugriff (PDF)

Major phase I biotransformation pathways of Trichostatin a in rat hepatocytes and in rat and human liver microsomes

Drug metabolism and disposition, 2002-12, Vol.30 (12), p.1320-1328

2002

Volltextzugriff (PDF)

362P Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)

Annals of oncology, 2023-11, Vol.34, p.S1610-S1611

2023

Volltextzugriff (PDF)

Advances in chemistry and bioactivity of the genus Uncaria

Phytotherapy research, 2004-04, Vol.18 (4), p.259-274

Laus, G

2004

Volltextzugriff (PDF)

516MO Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)

Annals of oncology, 2023-11, Vol.34, p.S1671

2023

Volltextzugriff (PDF)

Lattice Architecture and Hydrogen-Bonding Networks of N-Aminoazolium and N,N‘-Diaminoazolium Chlorides

Crystal growth & design, 2006-02, Vol.6 (2), p.404-410

2006

Volltextzugriff (PDF)

MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study

European journal of cancer (1990), 2022-10, Vol.174, p.S122-S122

2022

Volltextzugriff (PDF)

P76.72 A PET and MRI Study Exploring Osimertinib Brain Exposure and Efficacy in EGFRm NSCLC CNS Metastases

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S620-S620

2021

Volltextzugriff (PDF)

Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non‐small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study

Clinical and translational science, 2023-06, Vol.16 (6), p.955-965

2023

Volltextzugriff (PDF)

Kinetics of acetonitrile-assisted oxidation of tertiary amines by hydrogen peroxide

Perkin 2 : an international journal of physical organic chemistry, 2001 (6), p.864-868

Laus, Gerhard

2001

Volltextzugriff (PDF)

Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection

Annals of oncology, 2019-10, Vol.30, p.v589

2019

Volltextzugriff (PDF)

1450P - Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection

Annals of oncology, 2019-10, Vol.30, p.v589-v589

2019

Volltextzugriff (PDF)

Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies

Annals of oncology, 2017-09, Vol.28, p.v482

2017

Volltextzugriff (PDF)

LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

P2.14-33 An Open-Label PET-MRI Study to Determine Brain Exposure of Osimertinib in Patients with EGFR Mutant NSCLC and CNS Metastases

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S842-S842

2019

Volltextzugriff (PDF)

Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)

Annals of oncology, 2019-11, Vol.30, p.ix158

2019

Volltextzugriff (PDF)

1450PFrequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Phase-out-compliant fluorosurfactants: unique methimazolium derivatives including room temperature ionic liquidsElectronic supplementary information (ESI) available: Detailed description of the synthesis and spectroscopic data, melting points, crystal structures, optimization of molecular structures, and surfactant properties of compounds. CCDC 1416726-1416728 and 1449695-1449697. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c7gc00571g

2017-07

Volltextzugriff (PDF)

Crystal structure of sodium 4-azido-1,2,3-triazolide monohydrate, Na(N3C2HN3) · H2O

Zeitschrift für Kristallographie. New crystal structures, 2005-12, Vol.220 (4), p.575-576

2005

Volltextzugriff (PDF)

Crystal structure of (E)-2-ruthenocenylethenylcobaltocenium hexafluorophosphate, [(C5H5)Ru(C12H10)Co(C5H5)] [PF6]

Zeitschrift für Kristallographie. New crystal structures, 2006-04, Vol.221 (1), p.103-104

2006

Volltextzugriff (PDF)

1 – 25 von 343

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(267)
Mit Volltextzugriff
(264)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(214)
Physical Sciences
(116)
Life Sciences & Biomedicine
(99)
Exact Sciences And Technology
(79)
Applied Sciences
(58)
Organic Polymers
(56)
Physicochemistry Of Polymers
(56)
Chemistry
(53)
Humans
(53)
Polymer Science
(44)
Animals
(39)
Male
(35)
Technology
(33)
Biological And Medical Sciences
(29)
Female
(29)
Preparation, Kinetics, Thermodynamics, Mechanism And Catalysts
(29)
Materials Science
(26)
Properties And Characterization
(26)
Crystallography
(24)
Materials Science, Multidisciplinary
(23)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study

Phase-out-compliant fluorosurfactants: unique methimazolium derivatives including room temperature ionic liquids

Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors

Ionic Liquids as Advantageous Solvents for Headspace Gas Chromatography of Compounds with Low Vapor Pressure

A metabolic screening study of trichostatin A (TSA) and TSA-like histone deacetylase inhibitors in rat and human primary hepatocyte cultures

Major phase I biotransformation pathways of Trichostatin a in rat hepatocytes and in rat and human liver microsomes

362P Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)

Advances in chemistry and bioactivity of the genus Uncaria

516MO Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)

Lattice Architecture and Hydrogen-Bonding Networks of N-Aminoazolium and N,N‘-Diaminoazolium Chlorides

MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study

P76.72 A PET and MRI Study Exploring Osimertinib Brain Exposure and Efficacy in EGFRm NSCLC CNS Metastases

Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non‐small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study

Kinetics of acetonitrile-assisted oxidation of tertiary amines by hydrogen peroxide

Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection

1450P - Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection

Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies

LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study

P2.14-33 An Open-Label PET-MRI Study to Determine Brain Exposure of Osimertinib in Patients with EGFR Mutant NSCLC and CNS Metastases

Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)

1450PFrequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection

Crystal structure of sodium 4-azido-1,2,3-triazolide monohydrate, Na(N3C2HN3) · H2O

Crystal structure of (E)-2-ruthenocenylethenylcobaltocenium hexafluorophosphate, [(C5H5)Ru(C12H10)Co(C5H5)] [PF6]

Suchergebnisse filtern